Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor

by Leonie D. H. Gossel, Catrin Heim, Lisa-Marie Pfeffermann, Laura M. Moser, Halvard B. Bönig, Thomas E. Klingebiel, Peter Bader, Winfried S. Wels, Michael Merker, Eva Rettinger
Published 2021-03-01

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma

by Michael Merker, Michael Merker, Michael Merker, Juliane Wagner, Hermann Kreyenberg, Catrin Heim, Laura M. Moser, Winfried S. Wels, Winfried S. Wels, Winfried S. Wels, Halvard Bonig, Halvard Bonig, Zoltán Ivics, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Thomas Klingebiel, Thomas Klingebiel, Thomas Klingebiel, Peter Bader, Peter Bader, Peter Bader, Eva Rettinger, Eva Rettinger, Eva Rettinger
Published 2020-10-01